Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.47 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5105826 | 0.84 | CTSK (0.39) | CTSKKCNH2ALDH1A1F10 | |
| SCHEMBL5099470 | 0.84 | TACR1 (0.41) | CTSKKCNH2PTGDR2CYSLTR2CYSLTR1 | |
| SCHEMBL5099485 | 0.84 | CTSK (0.54) | CTSKKCNH2S1PR4S1PR5 | |
| SCHEMBL5099405 | 0.82 | ACLY (0.46) | CTSKKCNH2PTGDR2ALDH1A1KDM4E | |
| SCHEMBL5097034 | 0.82 | CTSK (0.47) | CTSKKCNH2S1PR1ALDH1A1KDM4E | |
| SCHEMBL5099924 | 0.81 | HDAC3 (0.45) | CTSKKCNH2KDM4E | |
| SCHEMBL9892688 | 0.79 | PTGDR2 (0.53) | PTGDR2ALDH1A1TACR1BACE1FABP4 | |
| SCHEMBL5106325 | 0.78 | PTGDR2 (0.48) | PTGDR2ALDH1A1 | |
| SCHEMBL5096891 | 0.74 | HDAC1 (0.52) | CTSKKCNH2KDM4EFAAH | |
| SCHEMBL9892681 | 0.73 | PTGDR2 (0.59) | PTGDR2ALDH1A1TACR1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449477-B2 | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B) | ELI LILLY AND COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070037796-A1 | e.g. 7-Phenyl-isoquinoline-5-sulfonic acid {2-[3 -(4-nitrophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt; antiviral, antineoplastic, anticarcinogenic agents; neoplasms | ELI LILLY AND COMPANY | 2007-02-15 | — | — | US | disclosed |
| EP-1689719-A1 | 7-PHENYL-ISOQUINOLINE-5-SULFONYLAMINO DERIVATIVES AS INHIBITORS OF AKT (PROTEINKINASE B) | ELI LILLY AND COMPANY (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054202-A1 | 7-PHENYL-ISOQUINOLINE-5-SULFONYLAMINO DERIVATIVES AS INHIBITORS OF AKT (PROTEINKINASE B) | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037796-A1 | e.g. 7-Phenyl-isoquinoline-5-sulfonic acid {2-[3 -(4-nitrophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt; antiviral, antineoplastic, anticarcinogenic agents; neoplasms | POLI, HRAS, CHUK | CTSK 2152/4885KCNH2 2049/4885PTGDR2 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.